Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Caprelsa in hereditary medullary thyroid carcinoma
NCT00098345Phase 2Completed
- Sponsor
- Sanofi
- Start
- Nov 2004
- Primary completion
- Feb 2008
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of vandetanib in medullary thyroid carcinoma (MTC), sponsored by Sanofi. Started Nov 2004; status: completed.
02
Drugs
vandetanib
03
Conditions
medullary thyroid carcinoma (MTC)
Beyond the preview
Go deeper on NCT00098345.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00098345.